94 related articles for article (PubMed ID: 16503420)
1. TCR vaccination in aluminum adjuvant protects against autoimmune encephalomyelitis.
Aroeira LS
Clin Immunol; 2006 Jun; 119(3):252-60. PubMed ID: 16503420
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice.
Offner H; Adlard K; Bebo BF; Schuster J; Burrows GG; Buenafe AC; Vandenbark AA
J Immunol; 1998 Sep; 161(5):2178-86. PubMed ID: 9725209
[TBL] [Abstract][Full Text] [Related]
3. Endogenous CD4+BV8S2- T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG-/- mice.
Matejuk A; Buenafe AC; Dwyer J; Ito A; Silverman M; Zamora A; Subramanian S; Vandenbark AA; Offner H
J Neurosci Res; 2003 Jan; 71(1):89-103. PubMed ID: 12478617
[TBL] [Abstract][Full Text] [Related]
4. A chimeric TCR-beta chain confers increased susceptibility to EAE.
Petersen TR; Lata R; Spittle E; Bäckström BT
Mol Immunol; 2007 Jul; 44(14):3473-81. PubMed ID: 17481734
[TBL] [Abstract][Full Text] [Related]
5. A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific for myelin oligodendrocyte glycoprotein.
Mendel I; Natarajan K; Ben-Nun A; Shevach EM
J Neuroimmunol; 2004 Apr; 149(1-2):10-21. PubMed ID: 15020060
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor peptide therapy for autoimmune encephalomyelitis: stronger immunization is necessary for effective vaccination.
Matsumoto Y; Tsuchida M; Hanawa H; Abo T
Cell Immunol; 1994 Feb; 153(2):468-78. PubMed ID: 8118876
[TBL] [Abstract][Full Text] [Related]
7. Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies.
Zhou SR; Whitaker JN
J Immunol; 1993 Feb; 150(4):1629-42. PubMed ID: 7679432
[TBL] [Abstract][Full Text] [Related]
8. A natural anti-T-cell receptor monoclonal antibody protects against experimental autoimmune encephalomyelitis.
Fernández-Malavé E; Stark-Aroeira L
J Neuroimmunol; 2011 May; 234(1-2):63-70. PubMed ID: 21396721
[TBL] [Abstract][Full Text] [Related]
9. Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice.
Link JM; Rich CM; Korat M; Burrows GG; Offner H; Vandenbark AA
Clin Immunol; 2007 Apr; 123(1):95-104. PubMed ID: 17257899
[TBL] [Abstract][Full Text] [Related]
10. Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector.
Chunduru SK; Sutherland RM; Stewart GA; Doms RW; Paterson Y
J Immunol; 1996 Jun; 156(12):4940-5. PubMed ID: 8648145
[TBL] [Abstract][Full Text] [Related]
11. Usage of Vbeta3.3 T-cell receptor by myelin basic protein-specific encephalitogenic T-cell lines in the Lewis rat.
Chan A; Gold R; Giegerich G; Herrmann T; Jung S; Toyka KV; Hartung HP
J Neurosci Res; 1999 Oct; 58(2):214-25. PubMed ID: 10502278
[TBL] [Abstract][Full Text] [Related]
12. Relapsing and remitting experimental autoimmune encephalomyelitis in B cell deficient mice.
Dittel BN; Urbania TH; Janeway CA
J Autoimmun; 2000 Jun; 14(4):311-8. PubMed ID: 10882057
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody against T-cell receptor alphabeta induces self-tolerance in chronic experimental autoimmune encephalomyelitis.
Lavasani S; Dzhambazov B; Andersson M
Scand J Immunol; 2007 Jan; 65(1):39-47. PubMed ID: 17212765
[TBL] [Abstract][Full Text] [Related]
14. Activation and control of pathogenic T cells in OSP/claudin-11-induced EAE in SJL/J mice are dominated by their focused recognition of a single epitopic residue (OSP58M).
Kaushansky N; Eisenstein M; Oved JH; Ben-Nun A
Int Immunol; 2008 Nov; 20(11):1439-49. PubMed ID: 18801757
[TBL] [Abstract][Full Text] [Related]
15. L-Selectin-deficient SJL and C57BL/6 mice are not resistant to experimental autoimmune encephalomyelitis.
Uboldi C; Döring A; Alt C; Estess P; Siegelman M; Engelhardt B
Eur J Immunol; 2008 Aug; 38(8):2156-67. PubMed ID: 18651702
[TBL] [Abstract][Full Text] [Related]
16. CD62L is required for the priming of encephalitogenic T cells but does not play a major role in the effector phase of experimental autoimmune encephalomyelitis.
Li O; Liu JQ; Zhang H; Zheng P; Liu Y; Bai XF
Scand J Immunol; 2006 Aug; 64(2):117-24. PubMed ID: 16867156
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with T cell receptor peptides using a conventional immunization protocol does not induce effective protection against autoimmune encephalomyelitis.
Tanuma N; Abe S; Shin T; Kojima T; Ishihara Y; Arai Y; Toyoshima S; Matsumoto Y
Cell Immunol; 1996 Feb; 168(1):85-90. PubMed ID: 8599843
[TBL] [Abstract][Full Text] [Related]
18. AlphaB-crystallin-reactive T cells from knockout mice are not encephalitogenic.
Wang C; Chou YK; Rich CM; Link JM; Afentoulis ME; van Noort JM; Wawrousek EF; Offner H; Vandenbark AA
J Neuroimmunol; 2006 Jul; 176(1-2):51-62. PubMed ID: 16844233
[TBL] [Abstract][Full Text] [Related]
19. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
Rich C; Link JM; Zamora A; Jacobsen H; Meza-Romero R; Offner H; Jones R; Burrows GG; Fugger L; Vandenbark AA
Eur J Immunol; 2004 May; 34(5):1251-61. PubMed ID: 15114658
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
